Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

Sanofi is the third company - along with J&J and Eli Lilly - to attempt to change the way it pays for medicines under the ...

Sanofi plans to phase in its model for different 340B-eligible providers starting early next year. The rebates would apply to 25 drugs, including Dupixent, an injectable used to treat inflammatory ...

French pharma company Sanofi has joined Ely Lilly and Johnson & Johnson in a challenge to the U.S.'s 340B drug discount ...

Sanofi plans to send a letter, reviewed by WSJ, to hospitals outlining its new model on Friday, the report said, citing ...

Sanofi joins Eli Lilly and Johnson & Johnson in seeking to change the 340B drug pricing program, facing pushback from HRSA and healthcare organizations.

Sanofi (SNY) is planning changes to its 340B plan on how it gives discounts to certain hospitals, planning to require institutions to provide ...